Prieto Valtuena
Jesus Prieto Valtuena, Navarra ES
Patent application number | Description | Published |
---|---|---|
20090117591 | Fibrosis Markers - The invention relates to the use of a combination of at least two markers that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A, for the in vitro detection of fibrotic alterations. In addition, the invention relates to a kit for determining the levels of said markers in a biological sample. | 05-07-2009 |
20090220532 | Agents and methods based on the use of the eda domian of fibronectin - This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent. | 09-03-2009 |
20100047231 | Immuno-Stimulant Combination for Prophylaxis and Treatment of Hepatitis C - The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus. | 02-25-2010 |
Jesus Prieto Valtuena, Pamplano ES
Jesus Prieto Valtuena, Pamplona(navarra) ES
Patent application number | Description | Published |
---|---|---|
20090130055 | Use of a Cytokine From the Interleukin-6 Family In the Preparation of a Composition For Combined Administration With Interferon-Alpha - The invention relates to the use of at least one cytokine from the IL-6 family −gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α. | 05-21-2009 |
Jesús Prieto ValtueÑa, Pamplona, Gipuzkoa ES
Patent application number | Description | Published |
---|---|---|
20160045463 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES - The present invention comprises the use of metalloprotease inhibitors for the treatment of polycystic liver diseases (PLDs). The invention particularly describes the use of Marimastat as the preferred metalloprotease inhibitor for the treatment of PLDs. Treatment with Marimastat is able to inhibit liver cystogenesis by blocking metalloproteolytic hyperactivity of polycystic cholangiocytes. | 02-18-2016 |
JesÚs Prieto ValtueÑa, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20100222280 | PEPTIDES WITH THE CAPACITY TO BIND TO TRANSFORMING GROWTH FACTOR beta 1 (TGF-beta 1) - The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze. | 09-02-2010 |
JesÚs Prieto ValtueÑa, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20090263410 | USE OF TGF-B1 INHIBITOR PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT - The present invention relates to the use of a peptide inhibiting TGF-β1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the preparation of an immune response modulating agent. | 10-22-2009 |
20100222280 | PEPTIDES WITH THE CAPACITY TO BIND TO TRANSFORMING GROWTH FACTOR beta 1 (TGF-beta 1) - The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze. | 09-02-2010 |
Jesüs Prieto Valtuena, Pamplona-Navarra ES
Patent application number | Description | Published |
---|---|---|
20100055736 | VIRAL VECTOR AND USES THEREOF - The invention relates to a viral vector comprising a mutated replicon of the Semliki Forest virus (SFV) in the nucleotide sequence encoding subunit nsp2 of the SFV replicase. Said viral vector can be used to generate stable cell lines which can constitutively express heterologous products of interest. | 03-04-2010 |
Jesus Maria Prieto Valtuena, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20120237535 | Therapeutic Compositions For The Treatment of HPV-Induced Diseases - The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells. | 09-20-2012 |
20130130225 | COMPOSITION FOR THE COLD STORAGE OF ORGANS - The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and/or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods. | 05-23-2013 |